应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AMAM Ambrx Biopharma Inc
停牌 06-14 16:00:00 EDT
28.00
+0.00
0.00%
最高
28.00
最低
28.00
成交量
0.00
今开
28.00
昨收
28.00
日振幅
0.00%
总市值
17.74亿
流通市值
5.86亿
总股本
6,335万
成交额
0.00
换手率
0.00%
流通股本
2,093万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec
Reuters · 01-18
美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec
美国研究综述-Burlington Stores、Carrols Restaurant Group、Mastec
Reuters · 01-17
美国研究综述-Burlington Stores、Carrols Restaurant Group、Mastec
隔夜美股全复盘(1.9)| 三大股指全天单边走强,芯片股领涨大市,英伟达大涨逾6%,股价创历史新高;波音大跌逾8%,全球多家航空公司对波音737 Max 9机型停飞检查
格隆汇 · 01-09
隔夜美股全复盘(1.9)| 三大股指全天单边走强,芯片股领涨大市,英伟达大涨逾6%,股价创历史新高;波音大跌逾8%,全球多家航空公司对波音737 Max 9机型停飞检查
今日优惠-合并与收购
Reuters · 01-09
今日优惠-合并与收购
综述 1-制药商以两笔癌症交易拉开行业会议序幕
Reuters · 01-08
综述 1-制药商以两笔癌症交易拉开行业会议序幕
BUZZ-Ambrx 生物制药公司因 J&J 宣布收购而大涨
Reuters · 01-08
BUZZ-Ambrx 生物制药公司因 J&J 宣布收购而大涨
市场消息:强生将收购生物制药公司Ambrx Biopharma
老虎资讯综合 · 01-08
市场消息:强生将收购生物制药公司Ambrx Biopharma
市场消息:强生(JNJ.N)将收购生物制药公司Ambrx Biopharma,股权价值20亿美元
新浪财经 · 01-08
市场消息:强生(JNJ.N)将收购生物制药公司Ambrx Biopharma,股权价值20亿美元
更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx
Reuters · 01-08
更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx
Ambrx Biopharma Inc (New)盘中异动 下午盘急速下挫5.05%
自选股智能写手 · 2023-12-21
Ambrx Biopharma Inc (New)盘中异动 下午盘急速下挫5.05%
暂无数据
公司概况
公司名称:
Ambrx Biopharma Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Ambrx Biopharma, Inc.是一家根据特拉华州法律成立的公司。该公司是一家临床阶段的生物制剂公司,专注于发现和开发一类新的工程精密生物制剂(EPBs),利用其专有的扩展遗传密码技术平台,使他们能够以特定地点的方式将合成氨基酸(SAA)整合到活细胞内的蛋白质中。它们的候选产品旨在克服传统结合方法的固有局限性,这些方法使用天然氨基酸进行非位点特异性结合,为治疗多个治疗领域的患者提供潜在的安全性和有效性益处。
发行价格:
--
{"stockData":{"symbol":"AMAM","market":"US","secType":"STK","nameCN":"Ambrx Biopharma Inc","latestPrice":28,"timestamp":1718395200000,"preClose":28,"halted":3,"volume":0,"delay":0,"floatShares":20929300,"shares":63352171,"eps":-0.237682,"marketStatus":"停牌","marketStatusCode":7,"change":0,"latestTime":"06-14 16:00:00 EDT","open":28,"high":28,"low":28,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.237682,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1718611200000},"adr":0,"listingDate":1623988800000,"adjPreClose":28,"adrRate":7,"volumeRatio":0},"requestUrl":"/m/hq/s/AMAM/tweets","defaultTab":"tweets","newsList":[{"id":"2404360394","title":"美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec","url":"https://stock-news.laohu8.com/highlight/detail?id=2404360394","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2404360394?lang=zh_cn&edition=full","pubTime":"2024-01-18 02:52","pubTimestamp":1705517520,"startTime":"0","endTime":"0","summary":" 路透1月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括伯灵顿百货公司、Carrols Restaurant Group 和 Mastec。要点 * Ambrx Biopharma Cayman Inc :贝雅将其评级下调至中性 * Burlington Stores Inc :Piper Sandler将其评级从中性上调至增持 * Carrols Restaurant Group Inc :Stephens将其评级从 \"增持 \"下调至 \"等权重\"。* Mastec Inc :贝尔德将其评级从 \"跑赢大盘 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","OWL","BKNG","LU0496365809.HKD","DOX","BAH","BMY","LU0310800965.SGD","ADP","GOLF","APLD","MS","C","BA","BURL","GOOGL","AMZN","BC","ACCD","GS","ALB","LU2552382058.USD","AMAM","BSX","AXL","JPM","AHH","ABNB","AEE","AFL","BK4551","ALNY","ABT","WFC","APLS","BWA","AXNX","ABBV","LU2552382215.SGD","SQ","ASO","GOLD","BWB","AMSC","ACIC","ALLK","AN","ANSS","AR","AIZ"],"gpt_icon":0},{"id":"2404048328","title":"美国研究综述-Burlington Stores、Carrols Restaurant Group、Mastec","url":"https://stock-news.laohu8.com/highlight/detail?id=2404048328","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2404048328?lang=zh_cn&edition=full","pubTime":"2024-01-17 15:02","pubTimestamp":1705474948,"startTime":"0","endTime":"0","summary":" 路透1月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括伯灵顿百货公司、Carrols Restaurant Group 和 Mastec。要点 * Ambrx Biopharma Cayman Inc :贝雅将其评级下调至中性 * Burlington Stores Inc :Piper Sandler将其评级从中性上调至增持 * Carrols Restaurant Group Inc :Stephens将其评级从 \"增持 \"下调至 \"等权重\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4576","BK4516","RTX","AMAM","LU0689472784.USD","FBK","OCSL","LU0106831901.USD","RENT","SWTX","LU1064131342.USD","MSCI","ZS","RKLB","LU1878469433.USD","LU0642271901.SGD","SNAP","META","BURL","CHPT","LU1244550221.USD","LU0708995401.HKD","HWC","TAST","APLS","RARE","ALLK","NOC","GS","IE00B19Z3B42.SGD","TDG","MTZ","IE00B66KJ199.SGD","DTM","LU0971096721.USD","MS","BK4211","PSN","DUK","IDYA","LU0130102774.USD","LU1989772923.USD","ORIC","RVLV","PNC","SPR","BK4144","CSWC","TGI","LU0320765489.SGD"],"gpt_icon":0},{"id":"2402917518","title":"隔夜美股全复盘(1.9)| 三大股指全天单边走强,芯片股领涨大市,英伟达大涨逾6%,股价创历史新高;波音大跌逾8%,全球多家航空公司对波音737 Max 9机型停飞检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2402917518","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2402917518?lang=zh_cn&edition=full","pubTime":"2024-01-09 07:57","pubTimestamp":1704758224,"startTime":"0","endTime":"0","summary":"三大股指全天单边走强,芯片股领涨大市,英伟达大涨逾6%,股价创历史新高;波音大跌逾8%,全球多家航空公司对波音737 Max 9机型停飞检查","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/682082","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09618","LU2326559502.SGD","LU2458330169.SGD","HARP","BK4512","LU1917777945.USD","LU2602419157.SGD","MRK","LU1242518857.USD","LU1064131342.USD","LU0820561818.USD","BK4564","BK4533","JD","IE0008368742.USD","LU2458330243.SGD","SG9999014559.SGD","AAPL","LU0689472784.USD","LU0889565916.HKD","LU1244550221.USD","SG9999015358.SGD","AMGN","LU0097036916.USD","LU0861579265.USD","NVDA","LU0466842654.USD","GPRO","LU0889566641.SGD","AMAM","IE00BFTCPJ56.SGD","BK4567","LU1242518931.SGD","IE00BD6J9T35.USD","JNJ","LU0056508442.USD","LU0289739343.SGD","SG9999014567.USD","LU2023250504.SGD","LU0011850046.USD","LU0820561909.HKD","BK4007","BK4122","IE00BJJMRY28.SGD","BK4516","AMD","BK4566","LU0149725797.USD","IE0009355771.USD","BA"],"gpt_icon":0},{"id":"2402617809","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2402617809","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2402617809?lang=zh_cn&edition=full","pubTime":"2024-01-09 00:58","pubTimestamp":1704733095,"startTime":"0","endTime":"0","summary":" 路透1月8日 - 截至格林尼治标准时间周一16时50分,报道了以下竞购、兼并、收购和处置: ** 强生 称,已同意以20亿美元收购药物开发商Ambrx Biopharma ,以获得属于一类靶向癌症疗法的药物,该疗法已引起其他制药商的兴趣。** 默克公司 表示,它将以约6.8亿美元的价格收购癌症药物开发商Harpoon Therapeutics ,用免疫疗法加强其肿瘤学产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HARP","LU0882574055.USD","SG9999001176.SGD","LU1804176565.USD","AMAM","PEP","IE00B1BXHZ80.USD","LU2361045086.USD","BSX","LU1057294990.SGD","LU1989764748.USD","BK4082","BK4534","LU0353189763.USD","LU1023059063.AUD","IE00B7SZLL34.SGD","BK4539","IE0002141913.USD","LU2491050154.USD","LU1989771016.USD","LU1989772923.USD","MRK","LU1732799900.SGD","AXNX","IE00BBT3K403.USD","IE0002270589.USD","LU2361044949.HKD","IE00B19Z3B42.SGD","LU0528227936.USD","LU1989772840.SGD","BK4532","SG9999001176.USD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU1280957306.USD","BK4533","LU0353189680.USD","LU1989764664.SGD","LU0122379950.USD","LU2361044865.SGD","LU2468319806.SGD","LU1261432733.SGD","LU1066051498.USD","LU2491050071.SGD","LU0792757196.USD","LU2491049909.HKD","SG9999015341.SGD","JNJ","LU0211331839.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2401596893","title":"综述 1-制药商以两笔癌症交易拉开行业会议序幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2401596893","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2401596893?lang=zh_cn&edition=full","pubTime":"2024-01-08 23:30","pubTimestamp":1704727809,"startTime":"0","endTime":"0","summary":" Bhanvi Satija/Sriparna Roy 路透1月8日 - 强生公司和默克公司周一在美国大型医疗保健会议的第一天宣布了收购癌症疗法开发商的计划,点燃了行业参与者的热情,他们希望这将是2023年结束后交易强劲的一年。据数据提供商LSEG Deals Intelligence称,在此之前,上个月在美国上市的生物技术交易价值约为250亿美元。另外,默克 表示将以约6.8亿美元的价格收购癌症药物开发商Harpoon Therapeutics ,从而获得正在接受肺癌和多发性骨髓瘤测试的早期免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655156.SGD","LU1718418525.SGD","LU1066051498.USD","SG9999013999.USD","BK4080","LU0965509283.SGD","BSX","ADC","LU0861579265.USD","LU1074936037.SGD","LU1974910355.USD","BK4539","BK4585","IE00BLSP4452.SGD","SG9999001176.USD","BK4231","LU0114720955.EUR","LU2023250843.SGD","BK4533","IE0009355771.USD","HARP","AMAM","BK4139","LU2491050154.USD","LU0795875169.SGD","IE00B7SZLL34.SGD","SG9999015341.SGD","MRK","LU1066053197.SGD","LU0889566641.SGD","SG9999014542.SGD","SG9999014567.USD","LU2265009873.SGD","LU1291159041.SGD","AXNX","LU0466842654.USD","IE00B19Z3B42.SGD","BK4592","LU1244550494.USD","SGXZ57979304.SGD","BK4516","LU2133065610.SGD","LU1244550577.SGD","BK4559","JNJ","LU0353189763.USD","LU1732799900.SGD","LU1506573853.SGD","BK4588","LU1804176565.USD"],"gpt_icon":0},{"id":"2401955887","title":"BUZZ-Ambrx 生物制药公司因 J&J 宣布收购而大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2401955887","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2401955887?lang=zh_cn&edition=full","pubTime":"2024-01-08 21:14","pubTimestamp":1704719643,"startTime":"0","endTime":"0","summary":" 1月8日 - ** Ambrx生物制药公司 的股价在盘前交易中上涨了一倍多,达到27.5美元。** 强生公司 称, ,它已同意以20亿美元收购药物开发商AMAM,以获得其癌症靶向疗法的使用权。** 强生公司将以每股28美元的价格收购Ambrx,与该股上次收盘价相比溢价约105%。** Ambrx正在开发的疗法属于被称为抗体-药物共轭物的药物类别,研究人员将其描述为 \"制导导弹\",可靶向癌细胞并最大限度地减少对健康组织的损害。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0114720955.EUR","LU0466842654.USD","LU1496350171.SGD","LU0820561818.USD","LU0708994859.HKD","AMAM","LU0689472784.USD","BK4534","BK4592","LU1935042991.SGD","BK4539","IMGN","LU2023251221.USD","BUZZ","BK4532","LU0795875169.SGD","LU1074936037.SGD","IE0004445239.USD","LU1244550221.USD","LU0310799852.SGD","LU1989772840.SGD","BK4504","LU0122379950.USD","LU0211327993.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","IE00B19Z3B42.SGD","JNJ","LU1551013342.USD","LU1839511570.USD","LU0820561909.HKD","IE0009355771.USD","LU0128525929.USD","LU1280957306.USD","LU1551013425.SGD","ABBV","LU1989772923.USD","LU1066051498.USD","LU1267930573.SGD","BK4533","LU1066053197.SGD","IE00B7SZLL34.SGD","LU1732799900.SGD","LU0882574055.USD","IE0002141913.USD","LU0310800379.SGD","LU1506573853.SGD","LU0211328371.USD","LU1989771016.USD"],"gpt_icon":0},{"id":"1170220477","title":"市场消息:强生将收购生物制药公司Ambrx Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1170220477","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1170220477?lang=zh_cn&edition=full","pubTime":"2024-01-08 21:09","pubTimestamp":1704719344,"startTime":"0","endTime":"0","summary":"1月8日,Ambrx Biopharma盘前暴涨100%!市场消息:$强生(JNJ)$将收购生物制药公司Ambrx Biopharma,股权价值20亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4581","LU0114720955.EUR","LU2602419157.SGD","LU1506573853.SGD","JNJ","BK4532","SG9999001440.SGD","LU1732799900.SGD","LU0792757196.USD","LU0889566641.SGD","LU2468319806.SGD","IE00B19Z3581.USD","LU2133065610.SGD","LU1244550494.USD","BK4504","LU0912757837.SGD","LU1585245621.USD","AMAM","LU0795875169.SGD"],"gpt_icon":0},{"id":"2401304956","title":"市场消息:强生(JNJ.N)将收购生物制药公司Ambrx Biopharma,股权价值20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2401304956","media":"新浪财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2401304956?lang=zh_cn&edition=full","pubTime":"2024-01-08 20:56","pubTimestamp":1704718578,"startTime":"0","endTime":"0","summary":"市场消息: 强生 (JNJ.N)将收购生物制药公司Ambrx Biopharma,股权价值20亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024010821072081a5202c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024010821072081a5202c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4581","LU0114720955.EUR","LU1066051498.USD","BK4533","LU2602419157.SGD","BK4007","BK4550","IE00B19Z3B42.SGD","IE0002270589.USD","LU1506573853.SGD","JNJ","SG9999001440.SGD","SG9999002232.USD","BK4588","LU0122379950.USD","LU1023059063.AUD","LU1074936037.SGD","LU1732799900.SGD","LU0640476718.USD","LU0795875086.SGD","LU1244550221.USD","BK4559","LU0792757196.USD","LU0889566641.SGD","SG9999002224.SGD","BK4592","IE00B7SZLL34.SGD","LU1935042991.SGD","LU2468319806.SGD","LU1244550577.SGD","LU2347655156.SGD","LU1261432733.SGD","BK4534","BK4139","LU0466842654.USD","LU1267930813.SGD","LU0234572021.USD","BK4568","LU1066053197.SGD","LU1244550494.USD","LU1732800096.USD","BK4504","LU0912757837.SGD","LU1057294990.SGD","LU1585245621.USD","AMAM","LU0795875169.SGD","LU1280957306.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2401930011","title":"更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx","url":"https://stock-news.laohu8.com/highlight/detail?id=2401930011","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2401930011?lang=zh_cn&edition=full","pubTime":"2024-01-08 20:44","pubTimestamp":1704717884,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (增加交易细节,背景贯穿始终) 路透1月8日 - 强生 周一表示,已同意以 20 亿美元收购药物开发商 Ambrx Biopharma ,以获得其癌症靶向疗法产品组合。 J&J将以每股28美元的价格收购Ambrx,与该股上次收盘价相比溢价约105%。 Ambrx公司正在开发的疗法属于抗体药物共轭物类药物(ADC),研究人员称其为 \"制导导弹\",可靶向癌细胞,并最大限度地减少对健康组织的损害。 J&J 的收购是该领域宣布的最新交易。11月,艾伯维 表示 (link),将以101亿美元现金收购ADC开发商ImmunoGen 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU1066053197.SGD","BK4007","BK4592","LU0889566641.SGD","AMAM","IE00B1BXHZ80.USD","LU1585245621.USD","LU1057294990.SGD","ADC","BK4534","LU1244550221.USD","LU1023059063.AUD","LU1732800096.USD","IE00B7SZLL34.SGD","BK4539","LU1430594728.SGD","LU0466842654.USD","SG9999002232.USD","LU2602419157.SGD","LU1244550494.USD","LU1244550577.SGD","SG9999002224.SGD","LU1732799900.SGD","LU1506573853.SGD","LU1935042991.SGD","LU0640476718.USD","IE0002270589.USD","BK4139","SG9999001440.SGD","IE00B19Z3B42.SGD","BK4231","LU0912757837.SGD","BK4588","BK4504","LU1074936037.SGD","LU1280957306.USD","LU1032466523.USD","BK4533","LU0122379950.USD","LU1267930813.SGD","LU2468319806.SGD","LU0114720955.EUR","LU1261432733.SGD","LU1066051498.USD","LU0792757196.USD","BK4550","BK4581","JNJ","LU0795875169.SGD"],"gpt_icon":0},{"id":"2393611496","title":"Ambrx Biopharma Inc (New)盘中异动 下午盘急速下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2393611496","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2393611496?lang=zh_cn&edition=full","pubTime":"2023-12-21 04:02","pubTimestamp":1703102562,"startTime":"0","endTime":"0","summary":"北京时间2023年12月21日04时02分,Ambrx Biopharma Inc 股票出现异动,股价大幅下挫5.05%。Ambrx Biopharma Inc 股票所在的生物技术行业中,整体跌幅为1.21%。Ambrx Biopharma Inc 公司简介:Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122104024287e60b6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122104024287e60b6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AMAM","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ambrx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.9035},{"period":"1year","weight":0.9087},{"period":"ytd","weight":0.9663}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0646},{"period":"6month","weight":0.1565},{"period":"1year","weight":0.2263},{"period":"ytd","weight":0.1419}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ambrx Biopharma, Inc.是一家根据特拉华州法律成立的公司。该公司是一家临床阶段的生物制剂公司,专注于发现和开发一类新的工程精密生物制剂(EPBs),利用其专有的扩展遗传密码技术平台,使他们能够以特定地点的方式将合成氨基酸(SAA)整合到活细胞内的蛋白质中。它们的候选产品旨在克服传统结合方法的固有局限性,这些方法使用天然氨基酸进行非位点特异性结合,为治疗多个治疗领域的患者提供潜在的安全性和有效性益处。","exchange":"NASDAQ","name":"Ambrx Biopharma Inc","nameEN":"Ambrx Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ambrx Biopharma Inc(AMAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ambrx Biopharma Inc(AMAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ambrx Biopharma Inc,AMAM,Ambrx Biopharma Inc股票,Ambrx Biopharma Inc股票老虎,Ambrx Biopharma Inc股票老虎国际,Ambrx Biopharma Inc行情,Ambrx Biopharma Inc股票行情,Ambrx Biopharma Inc股价,Ambrx Biopharma Inc股市,Ambrx Biopharma Inc股票价格,Ambrx Biopharma Inc股票交易,Ambrx Biopharma Inc股票购买,Ambrx Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ambrx Biopharma Inc(AMAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ambrx Biopharma Inc(AMAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}